HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.

Shintaro Nakano,Yasuyuki Kawamoto,Satoshi Yuki,Kazuaki Harada,Susumu Sogabe,Masayoshi Dazai,Atsushi Sato,Atsushi Ishiguro,Michio Nakamura,Shinya Kajiura,Yasuo Takahashi,Hidenori Karasaki,Miki Tateyama,Kazuteru Hatanaka,Yasushi Tsuji,Takahide Sasaki,Yoshiaki Shindo,Tomoe Kobayashi,Yuh Sakata,Yoshito Komatsu

HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.

2020

TPS4668Background: Combination chemotherapy with oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) showed improved survival compared to gemcitabine monotherapy for patients with met...

Keywords:

Metastatic pancreatic cancer
Oncology
Internal medicine
Irinotecan
first line treatment
Phases of clinical research
Combination therapy
Pathology
Oxaliplatin
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations